BioCardia, Inc. (BCDA)
Largest Insider Buys in Sector
BCDA Stock Price History Chart
BCDA Stock Performance
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Insider Activity of BioCardia, Inc.
Over the last 12 months, insiders at BioCardia, Inc. have bought $7,462 and sold $55,815 worth of BioCardia, Inc. stock.
On average, over the past 5 years, insiders at BioCardia, Inc. have bought $567,966 and sold $55,815 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Altman Peter (President and CEO) — $7,462.
The last purchase of 4,000 shares for transaction amount of $3,484 was made by Altman Peter (President and CEO) on 2023‑08‑17.
List of Insider Buy and Sell Transactions, BioCardia, Inc.
| 2024-01-19 | Sale | FROST PHILLIP MD ET AL | 10 percent owner | 129,802 0.5902% | $0.43 | $55,815 | -10.14% | |
| 2023-08-17 | Altman Peter | President and CEO | 4,000 0.0199% | $0.87 | $3,484 | -51.57% | ||
| 2023-08-14 | Altman Peter | President and CEO | 4,500 0.022% | $0.88 | $3,978 | -52.64% | ||
| 2023-05-26 | Altman Peter | President and CEO | 6,200 0.0264% | $1.60 | $9,920 | -75.30% | ||
| 2022-12-16 | FROST PHILLIP MD ET AL | director | 595,238 3.3% | $1.68 | $1,000,000 | +9.94% | ||
| 2022-11-11 | Altman Peter | President and CEO | 1,400 0.0079% | $1.86 | $2,604 | +1.89% | ||
| 2022-11-10 | Altman Peter | President and CEO | 3,100 0.0176% | $1.87 | $5,797 | +1.08% | ||
| 2022-10-10 | McClung David | Chief Financial Officer | 2,000 0.0112% | $2.07 | $4,140 | -4.75% | ||
| 2022-09-23 | Altman Peter | President and CEO | 1,400 0.0079% | $1.87 | $2,618 | +6.99% | ||
| 2022-09-22 | Altman Peter | President and CEO | 3,100 0.017% | $1.81 | $5,611 | +7.57% | ||
| 2022-09-21 | Altman Peter | President and CEO | 2,750 0.0163% | $1.92 | $5,280 | +9.34% | ||
| 2022-01-11 | Altman Peter | President and CEO | 100 0.0006% | $1.87 | $187 | -2.14% | ||
| 2020-06-19 | Allen Jim L. | director | 142,850 1.6989% | $2.10 | $299,985 | +44.98% | ||
| 2020-06-19 | STERTZER SIMON H | director, 10 percent owner | 142,850 1.6989% | $2.10 | $299,985 | +44.98% | ||
| 2020-06-19 | Blank Andrew Scott | director | 142,850 1.6989% | $2.10 | $299,985 | +44.98% | ||
| 2020-03-24 | Altman Peter | President and CEO | 1,200 0.0185% | $2.90 | $3,480 | +3.09% | ||
| 2020-03-19 | Altman Peter | President and CEO | 400 0.0058% | $2.95 | $1,180 | -6.52% | ||
| 2020-03-18 | Altman Peter | President and CEO | 3,300 0.0555% | $2.53 | $8,349 | +27.05% | ||
| 2020-03-17 | Altman Peter | President and CEO | 200 0.0037% | $3.66 | $732 | -4.64% | ||
| 2020-03-12 | Altman Peter | President and CEO | 3,400 0.0413% | $3.15 | $10,710 | -26.97% |
Insider Historical Profitability
| FROST PHILLIP MD ET AL | 10 percent owner | 1896025 8.77% | $2.90 | 19 | 2 | +9.94% |
| Altman Peter | President and CEO | 447339 2.0692% | $2.90 | 61 | 0 | <0.0001% |
| Brooks Andrew A | CEO | 63560031 293.9953% | $2.90 | 11 | 0 | |
| BROOKS JONATHAN | director, 10 percent owner | 32045292 148.2247% | $2.90 | 1 | 2 | |
| Allen Jim L. | director | 668200 3.0907% | $2.90 | 1 | 0 | +44.98% |
| STERTZER SIMON H | director, 10 percent owner | 187983 0.8695% | $2.90 | 18 | 0 | +13% |
| Blank Andrew Scott | director | 142850 0.6607% | $2.90 | 1 | 0 | +44.98% |
| McClung David | Chief Financial Officer | 78518 0.3632% | $2.90 | 6 | 0 | <0.0001% |
| Morgan Thomas H. | director | 40419 0.187% | $2.90 | 3 | 8 | |
| GERAGHTY KENNETH G | director, 10 percent owner | 6221 0.0288% | $2.90 | 2 | 0 | |
| GOTTLIEB CORREY J | director | 3333 0.0154% | $2.90 | 1 | 0 | |
| MERCORELLA ANTHONY J | director | 333 0.0015% | $2.90 | 1 | 0 | |
| GERSTENBLATT RANDY | director | 66 0.0003% | $2.90 | 1 | 0 | |
| ISRAEL ROY | Chairman,CEO & President | 0 0% | $2.90 | 0 | 3 | |
| Good Kenneth W | director, 10 percent owner | 0 0% | $2.90 | 0 | 1 | |
| SPECHT WILLEM F | director | 0 0% | $2.90 | 0 | 1 | |
| Kvitnitsky Mikhail | 10 percent owner | 0 0% | $2.90 | 0 | 1 | |
| Richards Ronald N. | director | 0 0% | $2.90 | 1 | 1 | |
| GIULIANI RHEAUME PATRICIA A | VP, CFO & Treasurer | 0 0% | $2.90 | 0 | 1 |
Institutional Investor Ownership
No records found… | |||||||